Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effect of the addition of idelalisib
 to ofatumumab on progression-free survival (PFS) in participants with previously treated
 chronic lymphocytic leukemia (CLL).
Key Inclusion Criteria:

 -  Adults with previously treated recurrent CLL who have measurable lymphadenopathy

 -  Require therapy for CLL

 -  Have experienced CLL progression < 24 months since the completion of the last prior
 therapy

 -  Have disease that is not refractory to ofatumumab

 Note: Other protocol defined Inclusion/Exclusion criteria may apply.